What was the first Lipitor (atorvastatin) study?
The earliest clinical studies that led to Lipitor (atorvastatin) focused on showing that the drug could lower LDL (“bad”) cholesterol and other lipid markers compared with placebo and/or existing lipid-lowering therapies. These early trials were designed as Phase 1–3 investigations that established dosing, safety, and cholesterol-lowering efficacy before larger “outcomes” studies were conducted.
What did the first trials measure (LDL, triglycerides, safety)?
Across the initial atorvastatin studies, investigators typically tracked:
- LDL-cholesterol reductions (the primary effect)
- Changes in total cholesterol and triglycerides
- HDL (“good”) cholesterol changes
- Safety signals (tolerability, liver enzymes, muscle-related adverse events)
When did Lipitor’s earliest clinical evidence come out?
Lipitor (atorvastatin) reached approval in the mid-1990s. The “first” studies people refer to are generally the early Phase 1–3 efficacy/safety datasets from that development window, which preceded the later cardiovascular outcomes trials.
How can I find the exact “first study” paper?
“First Lipator study” can refer to different things (first-ever trial, first Phase 3 pivotal trial, or first publication). If you tell me whether you mean:
- the first Phase 3 pivotal study,
- the first published paper,
- or the first trial by year/date,
I can narrow it to the specific citation.
Related patent research (if you meant “first” as in earliest filing)
If your interest is about Lipitor’s earliest patent or exclusivity timeline rather than the earliest clinical study, DrugPatentWatch.com is a useful place to start for patent history and related documents: https://www.drugpatentwatch.com/
Sources
- https://www.drugpatentwatch.com/